Plasma Fractionation Market: Global Industry Outlook, Trends, and Future Opportunities (2025-2034)

The global plasma fractionation market was valued at USD 27.96 billion in 2024, primarily driven by the increasing demand for plasma-derived therapies such as immunoglobulins, albumin, and coagulation factors. As chronic diseases and rare immunodeficiency disorders become more prevalent, the adoption of plasma-based therapies is accelerating. The market is expected to expand at a CAGR of 6.70% during 2025 to 2034, reaching approximately USD 53.48 billion by 2034.

Get a free sample Report: https://shorturl.at/r7PXQ

This article explores an in-depth analysis of the plasma fractionation industry, offering insights into market size and share, trends, dynamics, growth factors, challenges, key players, and frequently asked questions.

Market Overview of Plasma Fractionation

Plasma fractionation is a sophisticated biotechnological process used to separate and extract valuable plasma proteins like albumin, immunoglobulins, and coagulation factors. These components are critical in treating patients with hemophilia, immune deficiencies, and autoimmune diseases.

Plasma fractionation plays a vital role in ensuring the availability of lifesaving therapeutic products, especially as blood plasma donations continue to grow. The increase in geriatric populations, surgical interventions, and trauma cases has also escalated the demand for plasma-based products globally.

Plasma Fractionation Market Size and Share Analysis

In 2024, the plasma fractionation market stood at USD 27.96 billion. North America holds the largest share, primarily due to established healthcare infrastructure, high plasma collection rates, and awareness of plasma-derived therapies. Europe follows closely, with countries like Germany and Spain contributing significantly through blood donation programs.

By 2034, the market is projected to reach USD 53.48 billion, with growing traction in Asia-Pacific and Latin America, where improving healthcare systems and rising awareness are fostering market expansion.

Key contributing factors to market share include:

Growing prevalence of chronic and rare diseases

Increasing awareness of plasma therapies

Expansion of plasma collection centers

Public-private partnerships to increase plasma accessibility

Read full report with table of content: https://shorturl.at/ZydxZ

Market Dynamics and Emerging Trends

Drivers of Growth

Increasing Incidence of Immunodeficiency Disorders: Rising cases of primary immunodeficiencies and chronic illnesses are fueling the demand for immunoglobulin-based therapies.

Technological Advancements: Automation and improved purification techniques in plasma fractionation enhance efficiency and product yield.

Growing Geriatric Population: Aging populations are more prone to diseases that require plasma-derived treatments.

Restraints

High Cost of Therapy: Plasma-derived treatments are often expensive due to the complex nature of the production process.

Stringent Regulatory Policies: Compliance with safety regulations for plasma products can slow down product launches.

Dependence on Human Plasma Donations: A limited and variable supply of plasma can impact production continuity.

Trends

Rising Investment in R&D: Companies are increasingly investing in research to develop recombinant alternatives and enhanced plasma products.

Shift Toward Recombinant Therapies: While plasma-derived therapies are critical, there's a growing preference for recombinant versions due to scalability and safety.

Plasma Fractionation Market Growth Outlook

From 2025 to 2034, the plasma fractionation market is expected to grow steadily at a CAGR of 6.70%, driven by:

Increasing awareness of plasma therapies

Expansion into emerging economies

Improved blood collection and testing technologies

Enhanced fractionation techniques boosting product yields

The market growth is especially strong in Asia-Pacific, where improving healthcare infrastructure and increased disease diagnostics are expanding access to plasma-derived treatments.

Opportunities and Challenges in the Plasma Fractionation Market

Opportunities

Expansion in Emerging Economies: Markets in India, China, and Brazil are experiencing improved healthcare access and rising plasma collection.

Public-Private Collaborations: Strategic partnerships can improve plasma donation rates and increase production capacities.

Recombinant Technology: Integration of recombinant techniques with plasma therapies offers potential for enhanced efficacy and reduced dependency on human donors.

Challenges

Plasma Shortages: The global market still faces occasional plasma shortages due to collection inefficiencies or pandemics.

Ethical Concerns: Donor compensation and safety regulations are under constant scrutiny.

Cold Chain Logistics: Plasma and plasma-derived products require strict temperature-controlled transportation and storage, increasing logistic costs.

Recent Developments in the Plasma Fractionation Industry

Takeda recently announced an expansion of its plasma-derived therapy manufacturing facilities in Japan and the U.S.

Grifols opened new plasma donation centers across Europe and the U.S., increasing its plasma collection capabilities.

CSL Plasma introduced digital donor engagement tools to enhance collection efficiency.

OCTAPHARMA invested in new purification technologies to improve yield and safety in immunoglobulin production.

Governments in Asia are increasing investment in blood donation infrastructure and public awareness campaigns, further boosting the supply chain.

Competitor Analysis in the Plasma Fractionation Market

The plasma fractionation industry is moderately consolidated with several key players dominating global and regional markets. Leading companies are focusing on expansion, strategic collaborations, and R&D investments to maintain competitiveness.

Key Market Players

CSL Plasma LLC: A global leader in plasma collection and manufacturing, known for its innovation in plasma therapies.

Grifols, S.A.: Operates numerous plasma collection centers and is a leading supplier of plasma-derived medicines worldwide.

Takeda Pharmaceutical Company Limited: Offers a wide range of plasma products and is investing in global capacity expansion.

Biotest Group: Focuses on immunology and hematology plasma-derived products.

Baxter International Inc.: Provides comprehensive plasma therapy solutions for chronic and rare diseases.

OCTAPHARMA AG: Specializes in human protein therapies from plasma and human cell lines.

KEDRION S.P.A: An Italian firm involved in the development, production, and distribution of plasma-derived therapies.

LFB S.A.: French biopharmaceutical company delivering innovative plasma-based treatments.

BIOTEST AG: A prominent player in Europe, focused on hematology and intensive care therapies.

SANQUIN: Dutch organization involved in both plasma collection and pharmaceutical manufacturing.

BIO PRODUCTS LABORATORY LTD.: UK-based supplier of high-quality plasma-derived products.

INTAS PHARMACEUTICALS LTD.: Expanding its footprint in biosimilars and plasma therapy markets.

GC Pharma: South Korea's leading biopharma firm in the field of plasma and recombinant proteins.

Emergent Biosolutions: Known for its plasma-derived treatments in biodefense and public health.

Japan Blood Products Organisation: Key contributor in Japan's national blood and plasma supply system.

These companies focus on global outreach, local production facilities, and innovations in plasma purification and fractionation.

Frequently Asked Questions (FAQs)
What is plasma fractionation?

Plasma fractionation is the process of separating blood plasma into its individual protein components like albumin, immunoglobulins, and clotting factors for therapeutic use.

What is the expected market value of plasma fractionation by 2034?

The global plasma fractionation market is projected to reach USD 53.48 billion by 2034, growing at a CAGR of 6.70% from 2025.

What factors are driving the plasma fractionation market?

Key drivers include rising cases of immune deficiencies, increased plasma donations, growing elderly population, and advances in fractionation technology.

Which regions hold the largest market share?

North America holds the largest share, followed by Europe. However, Asia-Pacific is emerging as a high-growth region due to improving healthcare infrastructure.

Who are the major players in the plasma fractionation market?

Major companies include CSL Plasma, Grifols, Takeda, OCTAPHARMA, Baxter, and Biotest, among others.

What are the challenges facing the industry?

Challenges include high therapy costs, dependence on human plasma donations, and complex logistics due to the need for cold chain supply.

What are the key trends to watch in this market?

Growth in recombinant alternatives

Expansion in plasma collection infrastructure

Rising government involvement in national blood programs

The plasma fractionation market is undergoing a transformative phase, bolstered by technological advancements, rising disease burden, and expanding healthcare access globally. As the industry grows from USD 27.96 billion in 2024 to USD 53.48 billion by 2034, stakeholders must focus on enhancing plasma collection, ensuring regulatory compliance, and developing innovative therapies to meet the rising global demand.

With strategic partnerships, emerging regional markets, and robust R&D pipelines, the industry offers promising opportunities to enhance global health outcomes through plasma-derived therapies.

Find More Report:

Topical Skin Infection Treatment Drug Pipeline Analysis: https://shorturl.at/w00pe

Warm Autoimmune Hemolytic Anemia Drug Pipeline Analysis: https://shorturl.at/SylfP

Spinal Fusion Drug Pipeline Analysis: https://shorturl.at/yVZVr

Recurrent or Metastatic Head and Neck Cancer Drug Pipeline Analysis: https://shorturl.at/0T4vA

Synovial Sarcoma Drug Pipeline Analysis: https://shorturl.at/gLD55

Media Contact:

Company Name: Claight Corporation
Contact Person: Deepanshu Choudhary, Digital Marketing
Email: sales@expertmarketresearch.com
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others. Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

This release was published on openPR.